[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574521":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":46,"id":50,"slug":20,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CHT102 infusion","EXPERIMENTAL","CHT102 will be dosing by arterial infusion.",[13],"Drug: CHT102",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","CHT102","CHT 102 : MSLN UCAR-T.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Jihui Hao, Ph.D","CONTACT","+86-02223340123","haojihui@tjmuch.com",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":20,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Tianjin Medical University Cancer Institute & Hospital","RECRUITING","Tianjin","China","CN",{"type":35,"coordinates":36},"Point",[37,38],117.17667,39.14222,{"lat":38,"lon":37},[41,42],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":23,"role":43,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[47],{"name":48,"class":49},"Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.","INDUSTRY","100574521",false,"NCT06760364","A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer","A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer","CHAMPION","Inclusion Criteria:\n\n1. Ability to understand and sign a written informed consent documen；\n2. At the date of signing ICF, 18 \\~70 years old, male or female；\n3. Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；\n4. Positive mesothelin expression;\n5. At least one measurable lesion at baseline per RECIST version 1.1；\n6. The expected survival time is more than 12 weeks;\n7. ECOG 0-1 points;\n8. Adequate organ functions.","ALL","18 Years","70 Years",{"count":61,"type":62},21,"ESTIMATED","INTERVENTIONAL",[65],"PHASE1","Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer",[68],"Advanced Pancreatic Cancers",[70,71,72,73],"Allogeneic CAR-T","Safety","Efficacy","PK","2025-04-07",{"date":76,"type":77},"2025-04-10","ACTUAL",{"date":79,"type":77},"2024-12-25",{"date":81,"type":62},"2039-12-24",{"name":5,"class":6},1]